Alzheimer disease trials in Mexico

In Mexico 11 Also abroad 815

11 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Where
Guadalajara, Mexico City, Monterrey, Saltillo, San Luis Potosí City, Tlalnepantla
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00
Phase 2/3Taking people
ACP-204 in Adults With Alzheimer's Disease Psychosis
Where
Coahuila, Estado de México, Mazatlán, Mexico City, Monterrey, Nuevo León, San Luis Potosí City, Sinaloa
Age
55 years to 95 years
People
1,074 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06159673 · EU 2023-507325-42-00
Phase 3Enrolling by invitation
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Where
Coahuila, Culiacán, Estado de México, Monterrey, San Luis Potosí City
Age
55 years to 95 years
People
752 worldwide
Run by
ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06194799 · EU 2023-507351-29-00
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Culiacán, México, Monterrey, Saltillo Centro, Zapopan, Zona Urbana Río Tijuana
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Where
Culiacán, México, Monterrey, Saltillo Centro, Zapopan, Zona Urbana Río Tijuana
Age
55 years to 90 years
People
500 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Guadalajara, Mexico City, Monterrey, Saltillo, San Luis Potosí City, Tlalnepantla
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
No phaseTaking people
Dominantly Inherited Alzheimer Network (DIAN)
Where
Mexico City
Age
18 years and over
People
700 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT00869817
Phase 2/3Taking people
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Mexico City
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT05552157
Phase 2/3Taking people
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Mexico City
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT06647498
No phaseEnrolling by invitation
Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy
Where
Monterrey
Age
4 years to 80 years
People
36
Run by
Healing Hope International
See details and how to joinNCT07521384
No phaseTaking people
Proteinopathies Expression in Skin of Neurodegenerative Disorders
Where
San Luis Potosí City
Age
45 years and over
People
40
Run by
Universidad Autonoma de San Luis Potosí
See details and how to joinNCT06528964